ACOD1 and neoplasm: To assess the impact of itaconate on the anti-tumor efficacy of OVA-LNP, we administered 4-octyl itaconate (4-OI), a cell-permeable derivative of itaconate, to B16-F10 tumor-bearing Irg1-/- mice.